My Size Grows 100%+ Upon Optimistic Revenue Outlook

Good morning. It's December 27th, and today we’ll cover the latest on UnitedHealth, Ark Invest, BioNTech and why My Size is surging in premarket trade.

Institutional-Grade Assets

A portfolio of income-generating assets anchored by nationally recognized tenants like Walmart and CVS is creating buzz among savvy investors.

With access to exclusive, institutional-grade investments, this opportunity offers a chance to diversify and build wealth in a stable, high-demand market.

Previous Close 📈

Key U.S. indices remained nearly flat yesterday. However, they are still in the green on a week-to-day basis.

What to Watch

The advanced U.S. Trade Balance in goods and Retail and Wholesale Inventories for November were released at 8:30 a.m.

No major earnings are scheduled for today.

Healthcare

$3.3 Billion Deal Between UnitedHealth and Amedisys Faces Further Delays

UnitedHealth Group and Amedisys extended the deadline for their $3.3 billion merger to address ongoing legal challenges from the U.S. Department of Justice (DOJ). The announcement today pushes the deadline to either 10 days after a final court ruling or December 31, 2025, whichever comes first.

The delay comes amid a DOJ lawsuit, joined by attorneys general from Maryland, New Jersey, and New York, seeking to block the deal over antitrust concerns. Regulators argue the merger could harm competition in the home health services market, impacting patients, insurers, and healthcare providers.

Initially announced in June 2022, UnitedHealth’s acquisition of Amedisys, a leading provider of home health and hospice care, was expected to close by December 27. The revised waiver agreement includes a regulatory break fee starting at $275 million, potentially rising to $325 million if asset divestitures are not completed by May 1, 2025.

Despite the hurdles, Amedisys shares rose 3.5% in premarket trading, reflecting investor optimism. UnitedHealth has previously faced and overcome similar legal challenges, such as the DOJ’s attempt to block its acquisition of Change Healthcare in 2022.

Investment Management

Cathie Wood Advocates for Tax Reform Amid Post-Election Market Surge

Cathie Wood, CEO of ARK Investment, has urged the incoming Trump administration to clarify its tax reform plans, including retroactive corporate and individual tax cuts to January 1, 2025. Wood emphasized that such measures could boost market confidence and accelerate economic growth.

Wood’s flagship ARK Innovation ETF has surged 17% since Trump’s election victory, with key holdings like Tesla and Coinbase posting gains of 54% and 7%, respectively. Wood credits the rally to optimism over Trump’s pro-innovation platform, which includes deregulation, AI development, and crypto-friendly policies.

While supporting Trump’s economic vision, Wood cautioned that delays in tax clarity could lead to hesitation among businesses and individuals. The fund manager has positioned ARK heavily in Tesla, reflecting her confidence in CEO Elon Musk’s vision for AI and autonomous vehicles. She is also reallocating investments into emerging players like Archer Aviation to capitalize on innovation-driven trends.

Wood is optimistic about Trump’s broader impact on financial markets, predicting a shift favoring innovative sectors. However, she acknowledged ongoing volatility in ARK’s funds.

Although Wood has not financially backed Trump, she has engaged with allies like Musk and Senator Cynthia Lummis to discuss policy directions, including advancements in digital assets.

Biotechnology

BioNTech Agrees to $1.26 Billion in Royalties to U.S. and UPenn

BioNTech has reached two major settlement agreements involving royalty payments for its COVID-19 vaccine, Comirnaty. The German biotech company will pay $791.5 million to the U.S. National Institutes of Health (NIH) and $467 million to the University of Pennsylvania (UPenn).

The settlement with the NIH stems from licensing agreements for certain patents held by the U.S. agency, under which the government was entitled to royalty payments. Separately, UPenn agreed to dismiss its lawsuit against BioNTech, which alleged underpayment of royalties.

According to UPenn’s claims, BioNTech utilized a sublicense to the university’s technology acquired in 2017 to develop its vaccine in partnership with Pfizer. This sublicense became critical in creating the mRNA-based Comirnaty, which has played a pivotal role in global vaccination efforts.

The combined $1.26 billion payout resolves disputes that have shadowed the vaccine maker’s operations and underscores the complexities of intellectual property agreements in rapidly developed pandemic-era technologies.

AI

Electricity reshaped the economy, creating the FAANG stocks and boosting GDP by over 4,900%. AI is going to do it again. Here's what to buy...

Movers and Shakers

Surf Air Mobility Inc. [SRFM] - Last Close: $5.49

Surf Air Mobility Inc. shares are up 30.42% in premarket trading after the company announced plans to cut potential future equity dilution by about 90%.

This move aims to strengthen their financial position and boost investor confidence.

My Take: While reducing equity dilution is a positive step, Surf Air Mobility's path to profitability remains challenging. Be cautious while investing here.

Crown Electrokinetics Corp. [CRKN] - Last Close: $0.13

Crown Electrokinetics Corp. (CRKN) shares are jumping 24% in premarket trading after CEO Doug Croxall's shareholder letter highlighting a positive outlook for 2025.

The firm expects full-year 2025 revenue between $30 million and $35 million and plans to launch a reverse stock split to meet Nasdaq bid-price rules.

My Take: Despite the recent surge, CRKN remains down over 99% year-to-date, so it might be best to leave this on your wait and watch list for now.

My Size, Inc. [MYSZ] - Last Close: $4.22

My Size, Inc. (MYSZ) shares are surging over 100% in premarket trading due to the company's projections of closing 2024 with $8.5 million in revenue—a 23% increase year-over-year—and aiming for $15 million by 2025.

It has also shared several positive updates on its AI-driven sizing solution, Naiz Fit.

My Take: Despite the jump, My Size is -19% YTD. Keep a close watch on this stock for future growth.

Income-Generating Assets

In uncertain markets, many investors struggle to find stable, high-performing assets to grow their portfolios. Volatile stocks and unpredictable returns can make it challenging to build lasting wealth.

Properties leased by nationally recognized tenants like Kroger, CVS, and Walmart, offering both stability and potential for strong returns, remain elusive to most.

These exclusive opportunities not only provide steady cash flow but also position investors for long-term appreciation in a market that prioritizes essential services.

Everything Else

  • Microsoft retains OpenAI tech access until the $100 billion AGI profit milestone is met.

  • Beijing’s probe into beef imports could impact Brazil, Argentina, and Australia.

  • Trident Techlabs eyes innovation with a majority stake in semiconductor company Sivaltech.

  • Lantronix strengthened its smart city and 5G focus with the NetComm Wireless acquisition.

  • Investor concerns over the 5:1 ratio send Nissan shares plunging the most in 26 years.

  • Italy greenlights Baykar’s purchase of Piaggio Aerospace to revive strategic assets.

That’s all for today. Thank you for reading. If you have any feedback, please reply to this email.

Best Regards,

— Adam Garcia
Elite Trade Club

Click here to get our daily newsletter straight to your cell for free.

P.S. Just like this newsletter, it's 100% free*, and you can stop at any time by replying STOP.